Viatris (VTRS) Stock

PITTSBURGH, Feb. 3, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) is set to announce its financial results for the fourth quarter and the entire year of 2024 on Thursday, February 27, 2025. Company leaders will hold a webcast at 8:30 a.m.

Viatris, created from the merger of Mylan and Pfizer's Established Brands, has experienced fluctuations in its stock price since it started in 2020. Last October, I recommended Viatris as a "Buy" because the management had finished "Phase 1" of their business transformation and began "Phase 2" of their strategy to achieve growth. The company sells both generic and established brand medications, but the revenue from established brands has been decreasing because of patent expirations and competition in the market.

We have put together a list of the 10 companies that are going against the market's positive trend. In this article, we will examine how Viatris Inc. (NASDAQ:VTRS) compares to other stocks. On Wednesday, all major Wall Street indices ended on a high note, as investors reacted positively to a lower-than-expected inflation rate in December.

At Zacks, we concentrate on the reliable Zacks Rank system, which highlights earnings estimates and changes in those estimates to identify excellent stocks. However, we also keep an eye on the most recent trends in value, growth, and momentum to support our top selections.

Viatris Inc. (NASDAQ:VTRS) will participate in the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025, at 11:15 AM ET. The company will be represented by several key executives, including CEO Scott Smith and CFO Doretta Mistras. Chris Schott from JPMorgan will also be part of the conference call.

Since 2021, we have classified Viatris as "neutral/hold." During this period, the stock has underperformed compared to Treasury bills, even though it has a strong double-digit "free cash flow yield." We will explain the reasons for this situation and why we are preparing to make a trade.

On Friday, Britain's competition regulator imposed a fine of 1.5 million pounds ($1.88 million) on the U.S. company Viatris. This penalty was for breaking a rule while they were looking into Theramex's purchase of the European rights to two of Viatris's women's healthcare products.

Viatris Inc. (NASDAQ:VTRS) held a conference call at the Jefferies London Healthcare Conference on November 21, 2024, at 5:30 AM ET. The company was represented by several key executives, including Scott Smith, the CEO, and Doretta Mistras, the CFO. Glen Santangelo from Jefferies also participated in the call, greeting everyone with a good morning.

Viatris Inc. (NASDAQ:VTRS) will be participating in the UBS Global Healthcare Conference on November 12, 2024, at 11:45 AM ET. The company's Chief Financial Officer, Doretta Mistras, will be present, along with Ashwani Verma from UBS, who specializes in small to mid-cap biotech and specialty pharmaceuticals. Welcome to everyone attending the conference.